Timothy Wilson, PhD. Managing Partner.
Tim founded Longcross Advisers in 2013. His 25 year career in the life sciences has encompassed investment banking, venture capital and equity research. He has worked with hundreds of private and public life science companies on both sides of the Atlantic at all stages of development from start-ups to multi-billion dollar corporations.
Starting as an Investment Analyst with Rothschild Asset Management in 1988, Tim subsequently became a highly rated biotechnology analyst consistently achieving top three rankings in the Greenwich Associates, Wall Street Journal and Reuters analyst surveys. He went on to become Head of Biotechnology Research for a variety of firms including Hambrecht and Quist, UBS, Cowen, Bear Stearns and Pacific Growth Equities.
Tim has substantial investment banking experience including public and private financings, mergers and acquisitions, licensing, asset sales and royalty monetizations. He has taken 21 biotechnology companies public including the first biotechnology IPOs in Germany, Denmark and Italy as well as financing such biotechnology industry leaders as Gilead, Actelion, Cephalon, BioChem Pharma, Cubist, Onyx, Amylin, MorphoSys and Evotec.
He holds a PhD in molecular biology from Cambridge University and a First Class Honours degree in biochemistry from Imperial College, London. He has published papers in Nature and the EMBO Journal. He is also a keen rally driver.
Rob Grundy, PhD.
Rob has a 15 year career in Pharma and Biotech which began as a research scientist in Schering-Plough in Milan and continued at GlaxoSmithKline in the NGI CEDD at Harlow where he led multi-disciplinary drug discovery teams and became involved in Business Development strategy.
Rob served as Chief Scientific Officer with Cerebricon, a preclinical CRO based in Finland where he was responsible for the scientific output, client liaison and quality control and was involved in business development and fund raising activity. In 2008, he became a founding member of Almac Discovery, building a pipeline of oncology therapeutic assets through licensing and strategic partnerships. Rob has significant experience in international asset search and evaluation, sell side business development, deal structuring and negotiation and serves as an advisor on life & health science strategy and commercialisation to government and academia.
Rob has PhD in Neuroscience from Manchester University, and an Honours degree in Pharmacology from Liverpool University.